Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 110,649

Document Document Title
WO/2015/175388A1
Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtai...  
WO/2015/174532A1
 Provided is an antidepressant useful against depression. A depression treatment agent configured by containing N-acetyl-D-mannosamine, and a pharmaceutical composition for the treatment of depression configured by containing an active...  
WO/2015/173133A1
The present invention relates to a 1-phenylalkanecarboxylic acid and at least one additional neuroprotective agent for use of in a combination therapy for the prevention or therapeutic treatment of proteinopathies and/or neurodegenerativ...  
WO/2015/175898A1
The present invention includes a method for diagnosis and treatment and prevention of Alzheimer's Disease comprising obtaining a biological sample from a subject suspected of having Alzheimer's Disease; determining the level of expressio...  
WO/2015/173258A1
The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its admini...  
WO/2015/174475A1
Provided is a composition for oral intake, having improved oral absorption of curcumin and/or an analog thereof and being capable of being easily and inexpensively produced. A complex of curcumin and/or an analog thereof and a water-solu...  
WO/2015/170122A1
The present invention relates to a CRH formulation and to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.  
WO/2015/170683A1
The objective of the present invention is to provide: an NOX inhibitor and an NFκB inhibitor, each having excellent activity; and a prophylactic or therapeutic agent for diseases associated with NOX or NFκB, which utilizes the NOX inhi...  
WO/2015/171765A2  
WO/2015/171802A1
Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-p yrido[2,1-a]isoquinolin-...  
WO/2015/171002A1
The present invention provides pharmaceutically acceptable salts of enantiomerically pure(R)-pirlindole and (S)-pirlindole compounds having an increased bioavailability profile for use in medicine.  
WO/2015/168800A1
Methods and products related to genome editing using the CRISPR/Cas9 system to introduce an A673T substitution into an APP gene, such as guide RNAs and recombinant proteins, are described for decreasing APP levels produced by a cell, and...  
WO/2015/169999A1
Compounds of formula (I), wherein R1-8 are as defined in the claims, exhibit a positive allosteric GABAB modulator effect and are thus useful as positive allosteric modulators of the GABAB receptor.  
WO/2015/171005A1
(S)-pirlindole or its pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising the same for use in the therapeutic treatment and prevention of pain.  
WO/2015/171004A1
(R)-pirlindole or its pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising the same for use in the therapeutic treatment and prevention of pain.  
WO/2015/171720A1
The methods of the present invention are useful for determining whether an individual has or is at risk of developing a neuroimmune-based psychiatric disorder by detecting the expression level of one or more cytokine receptors in a biolo...  
WO/2015/169180A1
Provided herein are novel piperazine compounds acting as selective serotonin reuptake inhibitors and/or the 5-HT1A receptor agonists. The invention also relates to the methods of preparing the compound and pharmaceutical composition, and...  
WO/2015/169999A8
Compounds of formula (I), wherein R1-8 are as defined in the claims, exhibit a positive allosteric GABAB modulator effect and are thus useful as positive allosteric modulators of the GABAB receptor.  
WO/2015/171547A1
Methods of treating cognitive impairment, and/or reducing or preventing one or more neuropsychiatric morbidities in a subject with a neurodegenerative disease or disorder are disclosed. The methods can include administering the subject a...  
WO/2015/167296A1
The present invention provides a novel use of protein phosphatase 1 and protein phosphatase inhibitor 2 associated with the prevention or treatment of amyotrophic lateral sclerosis. According to the present invention, protein phosphatase...  
WO/2015/167825A1
The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in whic...  
WO/2015/166045A3
The present invention relates to the treatment of neurodegenerative diseases, i.e. a group of chronic, progressive disorders characterized by the gradual loss of neurons in discrete areas of the central nervous system (CNS). Specifically...  
WO/2015/165980A2
The invention discloses a monocyte inducing agent and/or a monocyte activating agent and/or a monocyte recruiting agent for use in the treatment and prevention of AD.  
WO/2015/168616A1
An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor 7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are...  
WO/2015/165279A1
Provided are new polyfluoro-substituted pyrazolopyrimidine compounds or salts represented by formulae (I) to (IX), a preparation method therefor, and a method for using said compounds and a preparation thereof to treat and inhibit autoim...  
WO/2015/167226A1
The present invention relates to hyaluronic acid-rich node and duct system (HAR-NDS)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (NDSCs), which are adult s...  
WO/2015/168031A1
The present invention provides a buprenorphine dimer compound, wherein the two buprenorphine portions are linked via an ethylene spacer, wherein the spacer is bonded to the two opioid molecules via an ether bond. Pharmaceutical compositi...  
WO/2015/164984A1
Use of an inhibitor of the ErbB2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, Herceptin. A medicament for treatment or...  
WO/2015/165974A1
The invention discloses a pharmaceutical preparation comprising a non-Toll-like receptor (non-TLR) dependent immune stimulant in an effective amount for use in the treatment and prevention of dementias associated with amyloid deposition,...  
WO/2015/165382A1
Use of a pharmacodynamic active ingredient of ganoderma lucidum in preparing anti-depressant drugs, and anti-depressant drugs comprising the pharmacodynamic active ingredient of ganoderma lucidum, the pharmacodynamic active ingredient be...  
WO/2015/165968A1
The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with β-amyloid deposition, preferably AD.  
WO/2015/166370A1
The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or s...  
WO/2015/168000A1
Provided are methods for treating multiple sclerosis using a continuous regimen of estrogen in combination with periodic administration of a progestogen.  
WO/2015/165428A1
The invention relates to furo[3,2-b]pyridines substituted at least in position 5 as inhibitors of protein kinases, regulators or modulators, methods of preparation thereof, pharmaceutical compositions containing the compounds, and pharma...  
WO/2015/165085A1
The present invention relates to compounds of formula (I), wherein X is CH or N; L is a bond, -C(O)- or -C(O)NH-; Ar is phenyl or a five or six membered heteroaryl group, containing one or two N atoms; R1is halogen, lower alkyl, lower al...  
WO/2015/167890A1
A 5-HT2A receptor inverse agonist of the formula:, its uses and methods for its preparation are described.  
WO/2015/166938A1
 Provided is a raw material for a food additive which promotes the intracerebral release of monoamines such as dopamine and noradrenaline, and imparts a function to prevent cranial nerve disease and a function to improve brain function...  
WO/2015/165833A1
The present invention relates to the compound (2R,2'R)-bis(((((tetrahydro-2H-pyran- 4-yl)oxy)carbonyl)oxy)methyl) 1,1'-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for tre...  
WO/2015/168014A1
Pharmaceutically active homo-dimers of opioid and other pharmaceutically active agents characterized by a single phenolic hydroxyl group wherein the respective monomers are ether-linked through such groups by an ethylene residue. The dim...  
WO/2015/165980A3
The invention discloses a monocyte inducing agent and/or a monocyte activating agent and/or a monocyte recruiting agent for use in the treatment and prevention of AD.  
WO/2015/165352A1
The present invention provides a compound with a structure represented by general formula I or a pharmaceutically acceptable salt thereof, a preparation method for the compound or the salt, and a use of the compound or the pharmaceutical...  
WO/2015/166379A3
The present invention provides polymorphic forms of Vortioxetine of and its pharmaceutically acceptable salts. Specifically the present invention relates to the novel crystalline forms of Vortioxetine or its pharmaceutically acceptable s...  
WO/2015/168246A1
This invention relates to processes for preparing a JAKl inhibitor having Formula la: as well as new forms of the inhibitor.  
WO/2015/165961A1
The invention discloses a vaccine for use in the treatment and prevention of AD, wherein the vaccine contains an aluminium salt in an amount of at least 1.2 mg per dose, preferably at least 1.5 mg per dose, especially at least 1.8 mg (gi...  
WO/2015/165964A1
Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.  
WO/2015/166366A1
The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or s...  
WO/2015/165966A1
The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.  
WO/2015/165374A1
Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune sys...  
WO/2015/165835A1
The present invention relates to compounds of formula (I) wherein X is CR or N; R is hydrogen, halogen or lower alkyl; L is a bond, -C(O)- or -C(O)NH-; Ar is phenyl or a five or six membered heteroaryl group, containing one or two N atom...  
WO/2015/168322A1
Various aspects provide a method for treatment of motor and cognitive functions, comprising administering a composition comprising sodium nitrite and a pharmaceutical excipient to a subject.  

Matches 551 - 600 out of 110,649